C
Citius Pharmaceuticals Inc (CTXR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
$0.53
-0.01 (-1.40%)
Market Cap: $14.69M
Last updated: Nov 17, 2026 at 11:00 AM ET
Citius Pharmaceuticals Inc (CTXR) Valuation Multiples
Citius Pharmaceuticals (CTXR) trades at 1.9x sales and 0.2x book value. Its P/B of 0.2x is below its 5-year median of 1.2x. Its forward P/E is 0.3x.
Current Multiples
| Multiple | Value |
|---|---|
| P/E (trailing) | N/A |
| Forward P/E | 0.3x |
| Price to sales | 1.9x |
| Price to book | 0.2x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/B is 85.7% below 1.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/B | 0.2x | 1.2x | 1.4x |
Valuation History
Over the 9 year ends shown, its P/B ranged from 0.2x in 2025 to 31.6x in 2017. 2025 was the lowest of those years.
| Year end | Price | P/S | P/B |
|---|---|---|---|
| 2025 | $0.78 | 4.2x | 0.2x |
| 2024 | $4.00 | N/A | 0.5x |
| 2023 | $18.91 | N/A | 1.4x |
| 2022 | $19.75 | N/A | 28.8x |
| 2021 | $38.50 | N/A | 1.8x |
| 2020 | $25.50 | N/A | 2.0x |
| 2019 | $25.50 | N/A | 1.5x |
| 2018 | $26.00 | N/A | 0.8x |
| 2017 | $95.00 | N/A | 31.6x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About CTXR
What is CTXR's forward P/E ratio?
Citius Pharmaceuticals has a forward P/E ratio of 0.3x.
Is CTXR stock overvalued?
GNG's valuation label for CTXR is Undervalued.
What is CTXR's price to sales ratio?
Citius Pharmaceuticals has a price to sales ratio of 1.9x.
CTXR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors